Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Annual Review of Medicine

• Publication date

  2015-01-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1146/annurev-med-061813-012806PMID 25386930PMCID PMC5846123
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FRI0528 Canakinumab in Systemic Juvenile Idiopathic Arthritis: Impact on the Rate and Clinical Presentation of Macrophage Activation Syndrome

  2014cited by this paper
• Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model

  2014cited by this paper
• Whole‐Exome Sequencing Reveals Overlap Between Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Familial Hemophagocytic Lymphohistiocytosis

  2014cited by this paper
• Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab

  2013cited by this paper
• Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome.

  2012cited by this paper
• Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

  2012cited by this paper
• Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus.

  2012cited by this paper
• The limited role of interferon-γ in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness.

  2012cited by this paper
• Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6.

  2012cited by this paper
• Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

  2012cited by this paper
• Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment

  2012cited by this paper
• Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis

  2012cited by this paper
• Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children.

  2012cited by this paper
• Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases

  2012cited by this paper
• Protection from Inflammatory Organ Damage in a Murine Model of Hemophagocytic Lymphohistiocytosis Using Treatment with IL-18 Binding Protein

  2012cited by this paper
• Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients.

  2011cited by this paper
• Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH.

  2011cited by this paper
• Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice.

  2011cited by this paper
• Serum Neopterin Levels as a Diagnostic Marker of Hemophagocytic Lymphohistiocytosis Syndrome

  2011cited by this paper
• Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice

  2011cited by this paper
• Hemophagocytosis causes a consumptive anemia of inflammation

  2011cited by this paper
• Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.

  2011cited by this paper
• An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis

  2011cited by this paper
• Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis.

  2011cited by this paper
• How I treat hemophagocytic lymphohistiocytosis.

  2011cited by this paper
• Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.

  2011cited by this paper
• The incidence of macrophage activation syndrome in children with rheumatic disorders.

  2011cited by this paper
• Inherited defects causing hemophagocytic lymphohistiocytic syndrome

  2011cited by this paper
• Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome

  2011cited by this paper
• Macrophage Activation Syndrome in the Acute Phase of Kawasaki Disease

  2010cited by this paper
• Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis.

  2010cited by this paper
• Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.

  2010cited by this paper
• Macrophage activation syndrome/hemophagocytic lymphohistiocytosis and Kawasaki disease

  2010cited by this paper
• Macrophage Activation Syndrome Treated with Anakinra

  2010cited by this paper
• High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein.

  2010cited by this paper
• Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis.

  2009cited by this paper
• The role of rituximab in a case of EBV-related lymphoproliferative disease presenting with haemophagocytosis.

  2009cited by this paper
• Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin.

  2009cited by this paper
• Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients.

  2009cited by this paper
• Experience With Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome at a Single Institution

  2009cited by this paper
• Neutralization of IFNγ defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice

  2009cited by this paper
• Galectin-3, A fÒ-galactoside binding lectin affects cytokine secretion by human macrophages

  2009cited by this paper
• CONTEMPORARY CHALLENGES IN AUTOIMMUNITY IL-18 Activity in Systemic Lupus Erythematosus

  2009cited by this paper
• Anakinra for Systemic Juvenile Arthritis: The Rocky Mountain Experience

  2009cited by this paper
• Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11.

  2009cited by this paper
• Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms.

  2008cited by this paper
• Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis

  2008cited by this paper
• A Griscelli syndrome type 2 murine model of hemophagocytic lymphohistiocytosis (HLH)

  2008cited by this paper
• The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.

  2008cited by this paper
• Etanercept for therapy‐resistant macrophage activation syndrome

  2008cited by this paper
• A case of macrophage activation syndrome successfully treated with anakinra

  2008cited by this paper
• Macrophage activation and polarization.

  2008cited by this paper
• Immunotherapy of Familial Hemophagocytic Lymphohistiocytosis With Antithymocyte Globulins: A Single-Center Retrospective Report of 38 Patients

  2007cited by this paper
• Specific gene expression profiles in systemic juvenile idiopathic arthritis.

  2007cited by this paper
• HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

  2007cited by this paper
• Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome.

  2007cited by this paper
• The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.

  2007cited by this paper
• Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis.

  2007cited by this paper
• Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.

  2007cited by this paper
• Interleukin-18 and the pathogenesis of inflammatory diseases.

  2007cited by this paper
• Perforin and granzymes have distinct roles in defensive immunity and immunopathology.

  2006cited by this paper
• Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood.

  2006cited by this paper
• Rapid responses to anakinra in patients with refractory adult-onset Still's disease.

  2005cited by this paper
• Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

  2005cited by this paper
• Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

  2005cited by this paper
• Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11.

  2005cited by this paper
• Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome.

  2005cited by this paper
• Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages.

  2005cited by this paper
• Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome.

  2004cited by this paper
• An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder.

  2004cited by this paper
• The chemokine system in diverse forms of macrophage activation and polarization.

  2004cited by this paper
• Interferon- : an overview of signals, mechanisms and functions

  2004cited by this paper
• Interferon-gamma: an overview of signals, mechanisms and functions.

  2004cited by this paper
• Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3).

  2003cited by this paper
• Increased serum levels of interferon‐γ‐inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis

  2003cited by this paper
• Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis.

  2003cited by this paper
• Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review.

  2003cited by this paper
• Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome.

  2003cited by this paper
• The many faces of macrophage activation

  2003cited by this paper
• Adverse Outcomes in Primary Hemophagocytic Lymphohistiocytosis

  2002cited by this paper
• Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders.

  2002cited by this paper
• Is macrophage activation syndrome a new entity?

  2002cited by this paper
• A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18.

  2001cited by this paper
• Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease.

  2001cited by this paper
• Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy.

  2001cited by this paper
• Etanercept in the treatment of macrophage activation syndrome.

  2001cited by this paper
• Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients.

  2001cited by this paper
• Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders

  2001cited by this paper
• Successful treatment of thymoma‐associated pure red cell aplasia with intravenous immunoglobulins

  2000cited by this paper
• Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells.

  1999cited by this paper
• Perforin gene defects in familial hemophagocytic lymphohistiocytosis.

  1999cited by this paper
• Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis.

  1997cited by this paper
• Contemporary classification of histiocytic disorders

  1997cited by this paper
• Successful treatment of juvenile rheumatoid arthritis associated haemophagocytic syndrome by cyclosporin A with transient exacerbation by conventional-dose G-CSF.

  1997cited by this paper
• Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society.

  1997cited by this paper
• Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine.

  1996cited by this paper
• Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases.

  1996cited by this paper
• Macrophage activation syndrome in systemic juvenile rheumatoid arthritis.

  1996cited by this paper
• Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis.

  1996cited by this paper
• Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management.

  1995cited by this paper

• A Review of Adenosine Deaminase 2 (ADA2) as a Biomarker of Monocyte/Macrophage Activation

  2026cites this paper
• TRATAMENTO DA SÍNDROME HEMOFAGOCÍTICA EM PACIENTES COM LÚPUS ERITEMATOSO SISTÊMICO: UMA REVISÃO SISTEMÁTICA

  2026cites this paper
• Association of IL6 Gene Polymorphisms with COVID-19 Susceptibility and Inflammation in Pregnant Women.

  2026influential citation
• Cytokine storm

  2026cites this paper
• Bufalin Inhibits Cytokine Storm by Regulating TLR4/TLR3 Signaling Pathway

  2026cites this paper
• Phagocytes Out of Control: Macrophage Activation Syndrome After the Use of Biologic Agents in the Treatment of Systemic Juvenile Idiopathic Arthritis.

  2025cites this paper
• Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance Systemic Juvenile Idiopathic Arthritis- Associated Lung Disease Cohort.

  2025cites this paper
• Transcriptomic evidence of cytokine storm and sepsis in little brown bats exposed to white-nose syndrome

  2025cites this paper
• Makrophagenaktivierungssyndrom: Notfall mit therapeutischen Herausforderungen

  2025cites this paper
• Intensive care unit admission and mortality in rheumatic diseases

  2025cites this paper
• Euthyroid Sick Syndrome as an Index of Prognosis in Severe COVID-19 Disease

  2025cites this paper
• Immunoregulatory effect of metformin in monocytes exposed to SARS-CoV-2 spike protein subunit 1

  2025cites this paper
• From rare to more common: The emerging role of omics in improving understanding and treatment of severe inflammatory and hyperinflammatory conditions.

  2025cites this paper
• Hemophagocytic Lymphohistiocytosis: Its Biochemical Basis and Clinical Implications

  2025influential citation
• Tofacitinib as a possible treatment in macrophage activation syndrome: a pilot single-center study in China

  2025cites this paper
• Pathogenic and Regulatory Roles of Fibrinolytic Factors in Autoimmune Diseases

  2025cites this paper
• Clinical significance of non-infectious procalcitonin elevation in Still's disease: A predictor of macrophage activation syndrome.

  2025cites this paper
• Pathogenetic Predictors of Complications of the New Coronavirus Infection SARS-COV-2

  2025cites this paper
• Lack of HLH in FMF

  2025cites this paper
• The Pathophysiology of Hemophagocytic lympho-histiocytosis (HLH) syndrome and insights from animal models.

  2025cites this paper
• Analysis of the clinical characteristics of five patients with Kawasaki disease complicated with macrophage activation syndrome in Baoding Hospital of Beijing Children’s Hospital, Capital Medical University

  2025cites this paper
• Biological Plausibility Between Long-COVID and Periodontal Disease Development or Progression

  2025cites this paper
• Acute Heart Failure in the Course of Macrophage Activation Syndrome Due to Newly Diagnosed Systemic Lupus Erythematosus: Case Presentation and Literature Review

  2024cites this paper
• Cytokine Storm Syndrome Associated with Systemic Juvenile Idiopathic Arthritis.

  2024cites this paper
• Improved survival in COVID‐19 related sepsis and ARDS treated with a unique “triple therapy” including therapeutic plasma exchange: A single center retrospective analysis

  2024cites this paper
• New discoveries in the genetics and genomics of systemic juvenile idiopathic arthritis

  2024cites this paper
• Macrophage Activation Syndrome in Viral Sepsis

  2024cites this paper
• A novel small non-coding RNA 562 mediates the virulence of Pseudomonas plecoglossicida by regulating the expression of fliP, a key component of flagella T3SS.

  2024cites this paper
• Unveiling the Role of SARS-CoV-2 or mRNA Vaccine Spike Protein in Macrophage Activation Syndrome (MAS).

  2024cites this paper
• Other Immunomodulatory Treatment for Cytokine Storm Syndromes.

  2024cites this paper
• PD-L1/PD-1 pathway: a potential neuroimmune target for pain relief

  2024cites this paper
• Canakinumab in the treatment of systemic juvenile idiopathic arthritis: a retrospective single center study in China

  2024cites this paper
• Biomarkers in Pediatric Hemophagocytic Lymphohistiocytosis With Central Nervous System Involvement: A Cohort Study

  2024cites this paper
• Acute kidney injury in critical care: complications of hemophagocytic lymphohistiocytosis

  2024cites this paper
• α2-antiplasmin is associated with macrophage activation and fibrin in a macrophage activation syndrome mouse model.

  2024cites this paper
• Salvage Therapy and Allogeneic Hematopoietic Cell Transplantation for the Severe Cytokine Storm Syndrome of Hemophagocytic Lymphohistiocytosis.

  2024cites this paper
• Increased ferritin, serum lactate dehydrogenase, and aspartate aminotransferase levels predict macrophage activation syndrome complicating systemic lupus erythematosus: a retrospective study

  2024cites this paper
• Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms

  2024cites this paper
• Delayed macrophage targeting by clodronate liposomes worsens the progression of cytokine storm syndrome

  2024cites this paper
• Features of hyperinflammation link the biology of EBV infection and cytokine storm syndromes.

  2024cites this paper
• The sharp edge of immunosuppressive treatments: infections

  2024cites this paper
• Hyperferritinemia Screening to Aid Identification and Differentiation of Patients with Hyperinflammatory Disorders

  2024cites this paper
• Canonical effects of cytokines on glomerulonephritis: A new outlook in nephrology

  2024cites this paper
• Prognostic factors in patients with secondary hemophagocytic lymphohistioc ytosis in a Chinese cohort

  2024cites this paper
• Fever, convulsions, and rash: a case report of neonatal lupus erythematosus with macrophage activation syndrome

  2024cites this paper
• EBV-triggered secondary macrophage activation syndrome in the backdrop of lupus in an adult.

  2024cites this paper
• 25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges

  2024cites this paper
• IL-1β-driven NF-κB transcription of ACE2 as a Mechanism of Macrophage Infection by SARS-CoV-2

  2024cites this paper
• Kombinierte Immunsuppression mit Cyclosporin A, Mycophenolatmofetil (MMF) und Dexamethason zur Aktivitätskontrolle einer rezidivierten, sekundären hämophagozytischen Lymphohistiozytose (sHLH) auf dem Boden eines systemischen Lupus erythematodes (SLE)

  2024cites this paper
• Systemic juvenile idiopathic arthritis–associated lung disease: A retrospective cohort study

  2024cites this paper
• Association between IL-1 single nucleotide polymorphisms and susceptibility to juvenile idiopathic arthritis: a systematic review and meta-analysis.

  2024cites this paper
• HSP70 contributes to pathogenesis of fulminant hepatitis induced by coronavirus.

  2024cites this paper
• The Scutellaria-Coptis herb couple and its active small-molecule ingredient wogonoside alleviate cytokine storm by regulating the CD39/NLRP3/GSDMD signaling pathway.

  2024cites this paper
• Predictors of disease course in systemic juvenile idiopathic arthritis.

  2024cites this paper
• Macrophage activation syndrome: a review of recent renal findings

  2024influential citation
• Hyperferritinemia screening to aid identification and differentiation of patients with hyperinflammatory disorders

  2024cites this paper
• Macrophage activation syndrome in Sepsis: from pathogenesis to clinical management

  2024cites this paper
• Microfluidic Immunoarray for Point-of-Care Detection of Cytokines in COVID-19 Patients

  2024cites this paper
• Leucine alleviates cytokine storm syndrome by regulating macrophage polarization via the mTORC1/LXRα signaling pathway

  2024cites this paper
• Kawasaki Disease-Associated Cytokine Storm Syndrome.

  2024cites this paper
• FEATURES OF CYTOKINE PRODUCTION DURING REHABILITATION AFTER COVID-19 IN PEOPLE LIVING IN THE NORTHERN REGIONS OF SIBERIA

  2023cites this paper
• Adjunctive use of oral MAF is associated with no disease progression or mortality in hospitalized patients with COVID-19 pneumonia: The single-arm COral-MAF1 prospective trial.

  2023cites this paper
• Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib

  2023cites this paper
• The nuclear cytokine IL-37a controls lethal cytokine storms primarily via IL-1R8-independent transcriptional upregulation of PPARγ

  2023cites this paper
• IL-10 and IFN-γ as markers for early recognition of pediatric systemic lupus erythematosus complicated with macrophage activation syndrome.

  2023cites this paper
• Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis

  2023cites this paper
• Insights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses

  2023cites this paper
• Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Show Differences in Autoantibody Signatures Based on Disease Activity

  2023cites this paper
• Autoimmune disease, including Lupus Panniculitis in association with Panniculitic Cell Lymphomas.

  2023cites this paper
• A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.

  2023cites this paper
• Free interleukin-18 is elevated in CD22 CAR T-cell–associated hemophagocytic lymphohistiocytosis–like toxicities

  2023cites this paper
• Immunobiology of pregnancy: from basic science to translational medicine.

  2023cites this paper
• Adult-onset Still’s disease complicated by macrophage activation syndrome during pregnancy: a case-based review

  2023cites this paper
• Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review

  2023cites this paper
• Clinical value of soluble fms-like tyrosine kinase 1 (sFlt-1) in adult secondary hemophagocytic lymphohistiocytosis

  2023cites this paper
• Emerging applications of extracellular vesicles in tumor therapy

  2023cites this paper
• Cytokines, chemokines, and cells growth factors in patients with mild to moderate SARS‐CoV‐2 infection: A case‐control study

  2023cites this paper
• IL-18 in Autoinflammatory Diseases: Focus on Adult Onset Still Disease and Macrophages Activation Syndrome

  2023influential citation
• Successful use of subcutaneous anakinra in hemophagocytic lymphohistiocytosis precipitated by candidiasis in a patient with systemic lupus erythematosus: A case report and description of a novel therapeutic regimen

  2023cites this paper
• Pathogenic Gene Spectrum and Clinical Implication in Chinese Patients with Lupus Nephritis

  2023cites this paper
• Severe Bone Marrow Aplasia Following Macrophage Activation Syndrome in Systemic Lupus Erythematosus.

  2023cites this paper
• Mouse models of systemic juvenile idiopathic arthritis and macrophage activation syndrome

  2023cites this paper
• BPOZ-2 is a negative regulator of the NLPR3 inflammasome contributing to SARS-CoV-2-induced hyperinflammation

  2023cites this paper
• Severe and life-threatening onset of systemic lupus erythematosus.

  2023cites this paper
• Immune mechanisms underlying COVID-19 pathology and post-acute sequelae of SARS-CoV-2 infection (PASC)

  2023cites this paper
• Opportunities and challenges in the diagnostic utility of dermal interstitial fluid

  2023influential citation
• Elevated Interleukin-10 Levels Are Associated with Low Platelet Count and Poor Prognosis in 90 Adult Patients with Hemophagocytic Lymphohistiocytosis

  2023cites this paper
• Complications of complications: diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis

  2023cites this paper
• Epigallocatechin gallate (EGCG) inhibits lipopolysaccharide‐induced inflammation in RAW 264.7 macrophage cells via modulating nuclear factor kappa‐light‐chain enhancer of activated B cells (NF‐κB) signaling pathway

  2023cites this paper
• Prognostic value of lipid profile in adult hemophagocytic lymphohistiocytosis

  2023cites this paper
• Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease

  2023cites this paper
• Biomarkers in Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome and Their Importance in COVID Era

  2022cites this paper
• Genetic and pharmacological targeting of GSDMD ameliorates systemic inflammation in macrophage activation syndrome.

  2022cites this paper
• The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer.

  2022cites this paper
• Anti-inflammatory and Immunostimulant Therapy with Lactobacillus fermentum and Lactobacillus plantarum in COVID-19: A Literature Review

  2022cites this paper
• Human pluripotent stem cell-derived macrophages and macrophage-derived exosomes: therapeutic potential in pulmonary fibrosis

  2022cites this paper
• Lung Involvement in Systemic Juvenile Idiopathic Arthritis: A Narrative Review

  2022cites this paper
• Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients

  2022cites this paper
• Neuropilin-1 in the pathogenesis of preeclampsia, HIV-1, and SARS-CoV-2 infection: A review

  2022cites this paper
• Evaluation of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis: A Single Center Experience

  2022cites this paper